Particle.news
Download on the App Store

NICE Approves Delgocitinib (Anzupgo) for NHS Use in Moderate to Severe Chronic Hand Eczema

NICE expects the home-use cream to cut phototherapy demand, freeing specialist capacity.

Overview

  • More than 62,000 people in England could benefit from the new NHS-backed option for debilitating hand eczema.
  • The treatment, marketed as Anzupgo by Leo Pharma, is expected to be available on the NHS within 90 days.
  • Adults apply the cream twice daily to affected areas on the hands and wrists at home.
  • NICE recommends the therapy for patients for whom steroid creams have failed or are unsuitable.
  • The option may reduce reliance on phototherapy and on oral retinoids that carry systemic side effects.